Immunome (IMNM) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Immunome (IMNM) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 40.4% versus a loss of 11.1%. Over five years, IMNM leads with a +11.0% price change compared with +9.3% for VRDN. Immunome is the larger company by market cap ($2.31 billion vs $2.11 billion), about 1.1 times the size, while Viridian Therapeutics is growing revenue faster (+23359.9% vs -23.2%).
Viridian Therapeutics converts more of its revenue into profit, with a net margin of -483.6% versus -3060.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | VRDN |
|---|---|---|
| Share price | $19.55 | $18.66 |
| Market cap | $2.31B | $2.11B |
| 1-day change | +1.24% | +1.74% |
| YTD return | -8.99% | -40.04% |
| 1-year return | +40.45% | -11.10% |
| 5-year return | +11.02% | +9.31% |
| EPS (TTM) | $-2.52 | $-3.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.94M | $70.85M |
| Revenue growth (YoY) | -23.23% | +23359.93% |
| Net income (latest FY) | $-212.39M | $-342.60M |
| Operating margin | -3228.83% | -512.91% |
| Net margin | -3059.99% | -483.57% |
| 52-week high | $30.06 | $34.29 |
| 52-week low | $13.54 | $13.18 |
| Distance from 52-week high | -34.96% | -45.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +80.05% | +96.95% |
| Average volume | 1.20M | 1.71M |
| Shares outstanding | 118.00M | 113.29M |
| Employees | 247 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMNM has outperformed VRDN by 51.5 percentage points over the past year.
- Viridian Therapeutics is more profitable, keeping -483.6 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
- Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs -23.23%).
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
IMNM vs VRDN FAQ
Which is bigger, Immunome or Viridian Therapeutics?
Immunome (IMNM) is larger, with a market capitalization of $2.31B compared with $2.11B for Viridian Therapeutics (VRDN).
Which stock has performed better over the past year, IMNM or VRDN?
IMNM returned +40.45% over the past 12 months, compared with -11.10% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.